Life expectancy in patients with multiple myeloma is increasing because of the availability of
an increasing number of novel agents with various mechanisms of action against the …

Over the last two decades, the utilization of various novel therapies in the upfront or salvage
settings has continued to improve survival outcomes for patients with Multiple Myeloma …

Multiple myeloma management has undergone profound changes in the past thanks to
advances in our understanding of the disease biology and improvements in treatment and …

Survival of myeloma patients has greatly improved with the use of autologous stem cell
transplantation and novel agents, such as proteasome inhibitors, immunomodulatory drugs …

Multiple myeloma (MM) is a clonal plasma cell malignancy affecting a predominantly elderly
population. The continued development of newer therapies with novel mechanisms of action …

Simple Summary The aim of this review is to provide an overview of the current scientific
evidence concerning the role of stem cell transplantation in multiple myeloma. During the …

Despite remarkable progress in survival with the availability of novel agents, an
overwhelming majority of patients with multiple myeloma (MM) relapse and the curability of …

Cellular therapies are a rapidly evolving approach to myeloma treatment, which bring a
unique mechanism of action with the potential to overcome drug resistance and induce long …

Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most
patients despite significant improvements achieved with modern therapy. Tumor evasion is a …

Background Despite recent advances, multiple myeloma (MM) remains incurable. However,
the appearance of allogeneic stem cell transplantation (allo-SCT) through graft-versus …